Concepedia

A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service

K.Y. Westerhout, M. Treur, Angelika Mehnert, Katie Pascoe, Imran Ladha, Jonathan Belsey

Journal of Medical Economics · 2015 · 19 citations · 22 references

DOIFull text

Open access

Abstract

Compared to other currently licensed treatment options, SMV + PR represents a cost effective treatment option for patients with chronic genotype 1 HCV infection.

References

22

Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

Michael Fried, Mitchell L. Shiffman, K. Rajender Reddy et al. · New England Journal of Medicine · 2002 · 6.4K citations

An Algorithm for the Grading of Activity in Chronic Hepatitis C

Pierre Bédossa, Thierry Poynard · Hepatology · 1996 · 4K citations · Full text

, , +14

Natural history of liver fibrosis progression in patients with chronic hepatitis C

Thierry Poynard, Pierre Bédossa, P Opolon · The Lancet · 1997 · 3K citations

, , +11

Guidelines for authors and peer reviewers of economic submissions to the BMJ

Michael Drummond, Tom Jefferson · BMJ · 1996 · 1.8K citations · Full text

, , +16

Clinical Outcomes after Transfusion-Associated Hepatitis C

Myron J. Tong, Neveen S. El-Farra, Andrew R. Reikes et al. · New England Journal of Medicine · 1995 · 1.2K citations · Full text